C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 417/06 (2006.01) A61K 31/445 (2006.01) A61P 29/00 (2006.01) C07D 211/60 (2006.01) C07D 401/06 (2006.01) C07D 405/06 (2006.01) C07D 409/06 (2006.01)
Patent
CA 2443600
The present invention relates to novel classes of compounds of formula (I) which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1- ("IL-1"), apoptosis-, interferon-.gamma. inducing factor- (IGIF), interferon-.gamma.- ("IFN-.gamma."), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-.gamma. production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-.gamma.-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.
L'invention concerne de nouvelles classes de composés de la formule I qui sont des inhibiteurs de caspase et de TNF-alpha. Elle concerne également des compositions pharmaceutiques renfermant ces composés. Ces composés et compositions pharmaceutiques conviennent particulièrement bien pour inhiber l'activité de caspase et de TNF-alpha, et peuvent être avantageusement utilisés comme agents contre caspase-, interleukine-1- ("IL-1"), apoptose-, facteur d'induction de l'interféron-.gamma. (IGIF), interféron-.gamma.- ("IFN-.gamma."), ou des maladies induites par TNF-alpha, telles que maladies inflammatoires, maladies autoimmunes, maladies osseuses destructives, maladies proliférantes, maladies infectieuses et maladies dégénératives. L'invention concerne en outre des procédés de préparation de ces composés. Elle concerne également des procédés permettant d'inhiber l'activité de caspase et de TNF-alpha et de réduire la production d'IGIF et de IFN-.gamma., ainsi que des procédés de traitement de caspase-, d'interleukine-1, d'apoptose et d'interféron-.gamma.- et de maladies induites par TNF-alpha au moyen desdits composés et compositions.
Diu-Hercend Anita
Golec Julian
Hercend Thierry
Knegtel Ronald
Lang Paul
Smart & Biggar
Vertex Pharmaceuticals Incorporated
LandOfFree
Heterocyclyldicarbamides as caspase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclyldicarbamides as caspase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclyldicarbamides as caspase inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1849281